Case Reports
doi: 10.1016/j.clgc.2012.04.005.
Epub 2012 Jun 1.
Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma
Affiliations
- PMID: 22658385
- DOI: 10.1016/j.clgc.2012.04.005
Item in Clipboard
Case Reports
Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma
Clin Genitourin Cancer.
2012 Dec.
No abstract available
Similar articles
-
Long-term response with sunitinib for metastatic renal cell carcinoma.Urology. 2006 Sep;68(3):672.e19-20. doi: 10.1016/j.urology.2006.03.042. Epub 2006 Sep 18. Urology. 2006. PMID: 16979716
-
Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.Am J Med Sci. 2010 Jun;339(6):580-1. doi: 10.1097/MAJ.0b013e3181dd1aa5. Am J Med Sci. 2010. PMID: 20421784
-
Intermittent sunitinib for metastatic renal cell carcinoma.Lancet Oncol. 2017 Mar;18(3):e139. doi: 10.1016/S1470-2045(17)30082-7. Epub 2017 Feb 3. Lancet Oncol. 2017. PMID: 28163004 No abstract available.
-
Sunitinib for metastatic renal cell carcinoma.Future Oncol. 2010 Sep;6(9):1377-85. doi: 10.2217/fon.10.94. Future Oncol. 2010. PMID: 20919823 Review.
-
Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.Clin Genitourin Cancer. 2006 Jun;5(1):23-5. doi: 10.1016/s1558-7673(11)70151-3. Clin Genitourin Cancer. 2006. PMID: 16859575 Review. No abstract available.
Cited by
-
A systematic review of non-standard dosing of oral anticancer therapies.BMC Cancer. 2018 Nov 22;18(1):1154. doi: 10.1186/s12885-018-5066-2. BMC Cancer. 2018. PMID: 30466406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
